By BRAD PERRIELLO Editor MassDevice Medtronic (NYSE:MDT) said Thursday, it’s launching a study of a new, combination treatment for atrial fibrillation using renal denervation and cardiac ablation. The Fridley, Minn.-based medical device giant said the 245-patient Symplicity AF trial is a prospective, randomized, multi-center feasibility study. It’s designed to compare RDN and pulmonary vein isolation …read more.